Get in Touch

Commercialization partnership from development to launch

Client Challenge

The client was seeking to commercialize lead Phase III asset in two rare disease indications.

Each indication has similar unmet need level but differed in clinical data and epidemiology.

P4A Solution

We built a unique partnership that covered both development and launch journey over a 36 month period.

Key partnership activities included:
  • Prioritisation of indications
  • Medical affairs support and implementation
  • Regulatory submission plan
  • Key markets pricing and access activities

The Successful Outcome

Indication sequence prioritized to position lead candidate with the highest value opportunity.

Stakeholder engagement activities helped achieve a favourable price and access position for the lead asset in the US and the EU.
The choice to go with a specialised orphan consultancy has paid off. The quality of service and advice we’ve been given has made our launch journey much easier to manage
European Business Unit Director
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact